Related Experiment Videos
Cell transplantation for Parkinson's disease: present status
René Drucker-Colín1, Leticia Verdugo-Díaz
1Depto. de Neurociencias, Instituto de Fisiología Celular, UNAM, México, DF. drucker@servidor.unam.mx
Cellular and Molecular Neurobiology
|June 23, 2004
Summary
Parkinson's disease (PD) treatments using cell transplantation show limited progress. Despite decades of research and new techniques, PD cell therapies still face the same challenges and yield similar results as early attempts.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Cellular Therapy
Background:
- Parkinson's disease (PD) involves the loss of dopamine neurons in the substantia nigra.
- Early PD stages benefit from dopaminergic network treatments.
- Cellular transplantation is explored for advanced PD to replace lost neurons.
Purpose of the Study:
- To review existing and emerging tissue grafts and cellular therapies for Parkinson's disease.
- To evaluate the efficacy and challenges of transplantation strategies in PD treatment.
Main Methods:
- Review of clinical trials involving adrenal medullary chromaffin cells and embryonic dopaminergic neurons.
- Examination of novel cellular treatments in animal models, including stem cells and transfected cells.
Main Results:
- Early clinical trials used adrenal and embryonic neural grafts.
- Current novel therapies include embryonic stem cells, porcine fetal cells, and transfected cells.
- Despite advancements, transplantation therapy for PD has not improved significantly over 20 years.
Conclusions:
- Cellular transplantation for Parkinson's disease remains a significant challenge.
- Current therapeutic outcomes for PD transplantation are comparable to initial historical attempts.
- Further research is needed to overcome persistent obstacles in PD cell-based therapies.